

Publications for Kellie Charles

2017

Shinko, D., Diakos, C., Clarke, S., Charles (nee Slaviero), K. (2017). Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine. *Clinical Pharmacology & Therapeutics*, 102(4), 599-610. [More Information]

2016

Charles (nee Slaviero), K., Harris, B., Haddad, C., Clarke, S., Guminski, A., Stevens, M., Dodds, T., Gill, A., Back, M., Veivers, D., Eade, T. (2016). Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and nonoropharyngeal patients. *BMC Cancer*, 16(1), 1-13. [More Information]

2015

Diakos, C., Charles (nee Slaviero), K., Chua, W., Howell, V., Clarke, S. (2015). Biomarkers in Metastatic Colorectal Cancer. In Victor R. Preedy and Vinood B. Patel (Eds.), *Biomarkers in Cancer*, (pp. 601-629). Dordrecht: Springer. [More Information]

Shen, C., Harris, B., Dawson, L., Charles (nee Slaviero), K., Hambley, T., New, E. (2015). Fluorescent sensing of monofunctional platinum species. *Chemical Communications*, 51(29), 6312-6314. [More Information]

2014

Diakos, C., Charles (nee Slaviero), K., McMillan, D., Clarke, S. (2014). Cancer-related inflammation and treatment effectiveness. *The Lancet Oncology*, 15(11), e493-e503. [More Information]

2013

Elens, L., Nieuweboer, A., Clarke, S., Charles (nee Slaviero), K., De Graan, A., Haufroid, V., Mathijssen, R., Van Schaik, R. (2013). CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. *Pharmacogenomics*, 14(2), 137-149. [More Information]

Elens, L., Nieuweboer, A., Clarke, S., Charles (nee Slaviero), K., De Graan, A., Haufroid, V., van Gelder, T., Mathijssen, R., Van Schaik, R. (2013). Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. *Pharmacogenetics and Genomics*, 23(3), 148-155. [More Information]

Guthrie, G., Charles (nee Slaviero), K., Roxburgh, C., Horgan, P., McMillan, D., Clarke, S. (2013). The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. *Critical Reviews in Oncology / Hematology (online)*,

88(1), 218-230. [More Information]

2012

Kulbe, H., Chakravarty, P., Leinster, D., Charles, K., Kwong, J., Thompson, R., Coward, J., Schioppa, T., Robinson, S., Gallagher, W., et al (2012). A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. *Cancer Research*, 72(1), 66-75. [More Information]

Chua, W., Clarke, S., Charles (nee Slaviero), K. (2012). Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer. *Supportive Care in Cancer*, 20(8), 1869-1874. [More Information]

2011

Chua, W., Kho, P., Moore, M., Charles (nee Slaviero), K., Clarke, S. (2011). Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. *Critical Reviews in Oncology/Hematology*, 79(3), 224-250. [More Information]

Chua, W., Charles (nee Slaviero), K., Baracos, V., Clarke, S. (2011). Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. *British Journal of Cancer*, 104(8), 1288-1295. [More Information]

Clarke, S., Chua, W., Moore, M., Kao, S., Phan, V., Tan, C., Charles (nee Slaviero), K., McMillan, D. (2011). Use of inflammatory markers to guide cancer treatment. *Clinical Pharmacology & Therapeutics*, 90(3), 475-478. [More Information]

2010

Moore, M., Chua, W., Charles (nee Slaviero), K., Clarke, S. (2010). Inflammation and Cancer: Causes and Consequences. *Clinical Pharmacology & Therapeutics*, 87(4), 504-508. [More Information]

2009

Chua, W., Moore, M., Charles (nee Slaviero), K., Clarke, S. (2009). Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer. *Current Opinion in Molecular Therapeutics*, 11(6), 611-622. [More Information]

Charles (nee Slaviero), K., Kulbe, H., Soper, R., Escorcio-Correia, M., Lawrence, T., Schultheis, A., Chakravarty, P., Thomson, R., Kollias, G., Smyth, J., et al (2009). The tumor-promoting actions of TNF- α involve TNFR1 and IL-17 in

ovarian cancer in mice and humans. *Journal of Clinical Investigation*, 119(10), 3011-2023. [More Information]

2008

Hagemann, T., Lawrence, T., McNeish, I., Charles (nee Slaviero), K., Kulbe, H., Thompson, R., Robinson, S., Balkwill, F. (2008). "Re-educating" tumor-associated macrophages by targeting NF- κ B. *The Journal of Experimental Medicine*, 205(6), 1261-1268. [More Information]

Brown, E., Charles (nee Slaviero), K., Hoare, S., Rye, R., Jodrell, D., Aird, R., Vora, R., Prabhakar, U., Nakada, M., Corringham, R., et al (2008). A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. *Annals of Oncology*, 19(7), 1340-1346. [More Information]

2007

Hagemann, T., Robinson, S., Thompson, R., Charles (nee Slaviero), K., Kulbe, H., Balkwill, F. (2007). Ovarian cancer cellâ€‘derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. *Molecular Cancer Therapeutics*, 6(7), 1993-2002. [More Information]

Harrison, M., Obermueller, E., Maisey, N., Hoare, S., Edmonds, K., Li, N., Chao, D., Hall, K., Lee, C., Timotheadou, E., Charles (nee Slaviero), K., et al (2007). Tumor necrosis Factor κ as a new target for renal cell carcinoma: Two sequential phase II trials of infliximab at standard and high dose. *Journal of Clinical Oncology*, 25(29), 4542-4549. [More Information]

2006

Hagemann, T., Wilson, J., Burke, F., Kulbe, H., Li, N., Pflüddemann, A., Charles (nee Slaviero), K., Gordon, S., Balkwill, F. (2006). Ovarian Cancer Cells Polarize Macrophages Toward A Tumor-Associated Phenotype. *Journal of Immunology*, 176(8), 5023-5032. [More Information]

Charles (nee Slaviero), K., Rivory, L., Stockler, M., Beale, P., Beith, J., Boyer, M., Clarke, S. (2006). Predicting the toxicity of weekly docetaxel in advanced cancer. *Clinical Pharmacokinetics*, 45(6), 611-622. [More Information]

Charles (nee Slaviero), K., Rivory, L., Brown, S., Liddle, C., Clarke, S., Robertson, G. (2006). Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. *Clinical Cancer Research*, 12(24), 7492-7497. [More Information]

Szlosarek, P., Charles (nee Slaviero), K., Balkwill, F. (2006). Tumour necrosis factor-alpha as a tumour promoter. *European Journal of Cancer*, 42(6), 745-750. [More Information]

2005

Hagemann, T., Wilson, J., Kulbe, H., Li, N., Leinster, D.,

Charles (nee Slaviero), K., Klemm, F., Pukrop, T., Binder, C., Balkwill, F. (2005). Macrophages Induce Invasiveness of Epithelial Cancer Cells Via NF- κ B and JNK. *Journal of Immunology*, 175(2), 1197-1205. [More Information]

Balkwill, F., Charles (nee Slaviero), K., Mantovani, A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. *Cancer Cell*, 7(3, March 2005), 211-217. [More Information]

2004

Charles (nee Slaviero), K., Clarke, S., McLachlan, A., Blair, E., Rivory, L. (2004). Population Pharmacokinetics Of Weekly Docetaxel In Patients With Advanced Cancer. *British Journal of Clinical Pharmacology*, 57(1), 44-53. [More Information]

2003

Charles (nee Slaviero), K., Read, J., Clarke, S., Rivory, L. (2003). Baseline Nutritional Assessment In Advanced Cancer Patients Receiving Palliative Chemotherapy. *Nutrition and Cancer: an international journal*, 46(2), 148-157. [More Information]

Charles (nee Slaviero), K., Clarke, S., Rivory, L. (2003). Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. *The Lancet Oncology*, 4(4), 224-232. [More Information]

2002

Rivory, L., Charles (nee Slaviero), K., Clarke, S. (2002). Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. *British Journal of Cancer*, 87(3), 277-280. [More Information]

2001

Rivory, L., Charles (nee Slaviero), K., Hoskins, J., Clarke, S. (2001). The erythromycin breath test for the prediction of drug clearance. *Clinical Pharmacokinetics*, 40, 151-158.

2000

Rivory, L., Charles (nee Slaviero), K., Seale, J., Hoskins, J., Boyer, M., Beale, P., Millward, M., Bishop, J., Clarke, S. (2000). Optimizing the erythromycin breath test for use in cancer patients. *Clinical Cancer Research*, 6, 3480-3485.